Posted in | Dendrimers | Nanobusiness

Genisphere’s 3DNA Dendrimer Technology Adapted for Lateral Flow Point-of-Care Assays

Genisphere has announced the adaption of its breakthrough 3DNA dendrimer signal amplification technology for use in lateral flow (LF) point-of-care (POC) assays, delivering enhanced sensitivity and facilitating a variety of new POC tests.

LF assays are a special and promising suite of POC tests intended to perform rapid diagnosis within clinically actionable timelines. Genisphere’s 3DNA signal amplifiers help in bringing new LF assays to the marketplace, which is otherwise not possible because of very low sensitivity, and provide a competitive edge to test-makers in the POC testing market, which is crowded with products limited by quantitative accuracy and sensitivity.

These advancements build on earlier signal amplification capabilities demonstrated in systems such as DNA and protein arrays, ELISA, and Luminex assays. Genisphere will exhibit its 3DNA dendrimer nanotechnology at the 012 American Association for Clinical Chemistry Annual Meeting and Clinical Lab Expo, which will be conducted in Los Angeles from July 15 to 19, 2012.

Genisphere’s proprietary 3DNA dendrimer technology has demonstrated a 64-fold increase in sensitivity when compared to typical non-dendrimer assays. This superior sensitivity enables the technology to decrease false negatives and considerably improve the accuracy of outcome readings. This technology will allow the POC market to provide high-sensitive rapid testing for a myriad of conditions, including coronary biomarkers, bacterial sepsis, infectious diseases, environmental and water testing, and food microbiological testing, which are not possible with existing systems.

Genisphere’s Vice President and Chief Operating Officer, Jim Kadushin stated that the company has achieved its objective of delivering a powerful and user-friendly reagent that can be used by manufacturers in their bioassay platforms with minimal adaptation and without end user modifications.

Source: http://www.genisphere.com

G.P. Thomas

Written by

G.P. Thomas

Gary graduated from the University of Manchester with a first-class honours degree in Geochemistry and a Masters in Earth Sciences. After working in the Australian mining industry, Gary decided to hang up his geology boots and turn his hand to writing. When he isn't developing topical and informative content, Gary can usually be found playing his beloved guitar, or watching Aston Villa FC snatch defeat from the jaws of victory.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thomas, G.P.. (2019, February 12). Genisphere’s 3DNA Dendrimer Technology Adapted for Lateral Flow Point-of-Care Assays. AZoNano. Retrieved on November 18, 2019 from https://www.azonano.com/news.aspx?newsID=25271.

  • MLA

    Thomas, G.P.. "Genisphere’s 3DNA Dendrimer Technology Adapted for Lateral Flow Point-of-Care Assays". AZoNano. 18 November 2019. <https://www.azonano.com/news.aspx?newsID=25271>.

  • Chicago

    Thomas, G.P.. "Genisphere’s 3DNA Dendrimer Technology Adapted for Lateral Flow Point-of-Care Assays". AZoNano. https://www.azonano.com/news.aspx?newsID=25271. (accessed November 18, 2019).

  • Harvard

    Thomas, G.P.. 2019. Genisphere’s 3DNA Dendrimer Technology Adapted for Lateral Flow Point-of-Care Assays. AZoNano, viewed 18 November 2019, https://www.azonano.com/news.aspx?newsID=25271.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit